NiKang Therapeutics

NiKang Therapeutics is a clinical-stage company focused on developing innovative small molecule drugs for cancer treatment. Their research centers around identifying and targeting specific molecular pathways involved in cancer development and progression. NiKang utilizes structural biology to design small molecules that interact with target proteins, and they consider various drug modalities to optimize the pharmacological profile of their compounds. NiKang has three lead compounds: NKT2152, NKT3447, and a KRAS G12D inhibitor. These small molecule drugs are against SHP2, HIF2a, and CDK2, which are notoriously difficult to target. NKT2152 and NKT3447 are currently in clinical trials. These are the first-in-human clinical tests for new cancer treatments involving these molecules.

Jobs: